Skip to main content

Development of novel vaccines to control infections wlth newly emerging highly pathogenic marek's disease viruses

Objective

Novel concepts to control newly emerging and highly pathogenic Marek's disease virus (vv+ MDV-1) are needed. Different antigen formulations, routes of vaccination, and biological adjuvant will be tested. DNA vaccines encoding MDV-1 antigens expressed in all stages of the virus' life cycle (lytic, latent, tumour stage) will be constructed, with an emphasis on antigens inducing a cytotoxic T cell response. The same proteins will also be expressed by recombinant Sindbis viruses. Modified live vaccines derived from a vv+ MDV-1 strain with a deletion in gB or gM shall be constructed using the bacterial artificial chromosome technique. The routes of vaccination will be
1) in-ovo vaccination and
2) vaccination of 1- day-old chickens via various routes. The cytokine profiles after MDV-1 infection will be analysed by developing new tools and test systems, and rational approaches to immune modulation using biological adjuvant will be developed and tested.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

FRIEDRICH-LOEFLER INSTITUTE FEDERAL RESEARCH INSTITUT FOR ANIMAL HEALTH
Address
Boddenblick 5 A
17498 Insel Riems
Germany

Participants (7)

BIOLOGICAL RESEARCH CENTRE - HUNGARIAN ACADEMY OF SCIENCES
Hungary
Address
62,Temesvari Krt. 62
6701 Szeged
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
France
Address
Centre De Recherche De Tours
37380 Monnaie , Nouzilly
INSTITUTE OF VIROLOGY - SLOVAK ACADEMY OF SCIENCES
Slovakia
Address
Dubravska Cesta 9
84246 Bratislava
Institute for Animal Health
United Kingdom
Address
Compton Laboratory Compton
RG16 0NN Newbury
KIMRON VETERINARY INSTITUTE
Israel
Address
Agricultural Center
50250 Bet Dagan
LOHMANN ANIMAL HEALTH GMBH & CO. KG
Germany
Address
Heinz-lohmann-strasse 4
27472 Cuxhaven
LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH
Germany
Address
Geschwister-scholl-platz 1
80539 Muenchen